Abstract | PURPOSE: METHODS: This is a review of the relevant literature regarding dasatinib development in CML (2003-2013). RESULTS:
Dasatinib demonstrates efficacy against most BCR-ABL mutations arising during imatinib therapy and is effective in treating patients with imatinib resistance due to other mechanisms. Randomized trial data show that first-line dasatinib provides superior responses compared with imatinib and enables patients to achieve early, deep responses correlated with improved longer-term outcomes. Dasatinib has a generally acceptable safety profile, with most adverse events (AEs) proving manageable and reversible. Cytopenias are commonly observed with dasatinib, and some nonhematologic AEs including pleural effusion have been consistently reported. CONCLUSION:
Dasatinib is an effective treatment option for patients with CML.
|
Authors | Andreas Hochhaus, Hagop Kantarjian |
Journal | Journal of cancer research and clinical oncology
(J Cancer Res Clin Oncol)
Vol. 139
Issue 12
Pg. 1971-84
(Dec 2013)
ISSN: 1432-1335 [Electronic] Germany |
PMID | 23942795
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Pyrimidines
- Thiazoles
- Fusion Proteins, bcr-abl
- Dasatinib
|
Topics |
- Antineoplastic Agents
(therapeutic use)
- Dasatinib
- Fusion Proteins, bcr-abl
(genetics)
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
(drug therapy, genetics)
- Mutation
- Neoadjuvant Therapy
(methods)
- Protein Kinase Inhibitors
(therapeutic use)
- Pyrimidines
(therapeutic use)
- Randomized Controlled Trials as Topic
- Thiazoles
(therapeutic use)
|